Congress Puts Focus Back On Drug Pricing With AbbVie Subpoena

 
• By Brenda Sandburg
  
Generate a summary of this article
Listen to this article
Beta

House Oversight Committee Chair says AbbVie has failed to comply with requests for documents in committee's investigation of the drug pricing of 12 pharma companies.

Congress and law as congressional subpoena and political legislation concept or government investigation and legislative reform in the United States with 3D illustration elements.
House ovesight committee plans to subpoena AbbVie for Humira and Imbruvica pricing information • Source: Shutterstock

Eighteen months after launching an investigation of the drug pricing practices of 12 companies, the House Committee on Oversight and Reform is singling out AbbVie Inc., claiming it has failed to turn over documents about the pricing of Humira (adalimumab) and Imbruvica (ibrutinib). The legal action brings the issue of drug pricing back to the forefront and could spur further policy debate as the presidential election campaign enters its final months.

Committee Chairwoman Carolyn Maloney, D-NY, announced on 1 September that she had sent a memo to committee members notifying them...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

PS-MarketAccess (Premium-2): Why Financial Scammers Are So Successful Targeting Doctors

 
• By Nabil

Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.

Senate Hearing On Ozempic, Wegovy Highlights Concerns About PBMs, International Price Disparities

 
• By Cathy Kelly

Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.

‘Alternative' PBMs Say Vertical Integration Unfairly Carving Them Out Of The Game

 
• By Sarah Karlin-Smith

Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.

US FDA Biologics Designation As Price Protection: Lilly Charts New Course With Retatrutide

 
• By Cathy Kelly

An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.

More from Market Access

analysis

Shot Across The Bow? Express Scripts Lawsuit Seeks To Derail Fall-Out From FTC PBM Report

 
• By Cathy Kelly

Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.

‘Alternative' PBMs Say Vertical Integration Unfairly Carving Them Out Of The Game

 
• By Sarah Karlin-Smith

Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.

UK MHRA First-Half New Drug Approvals Show Overwhelming Use Of EU Reliance Procedures

 
• By Ian Schofield

The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.